Ledadotin

Ledadotin is a drug-linker conjugate for ADC. Ledadotin consists of a Microtubule inhibitor (Auristatin F-hydroxypropylamide) (HY-P5191) and a linker (BCN-PEG2-Gly-NH-tri (βAla-GGGG-Ser (mPEG8) -βAla-γGlu-Ala) ) (HY-177562) . Ledadotin can be used for synthesis of ADC Emiltatug ledadotin (HY-177542) [1].

Product Specifications

CAS Number

[2669084-60-8]

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Field of Research

Cancer

Smiles

O=C(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC1=CC=CC=C1)NC([C@H]([C@H](OC)[C@H]2CCCN2C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)CCOCC(COCCC(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC3=CC=CC=C3)NC([C@H]([C@H](OC)[C@H]4CCCN4C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)(COCCC(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@H](C(OCCCNC([C@@H](CC5=CC=CC=C5)NC([C@H]([C@H](OC)[C@H]6CCCN6C(C[C@@H]([C@@H]([C@@H](CC)C)N(C([C@@H](C(C)C)NC([C@@H](C(C)C)N(C)C)=O)=O)C)OC)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC(CNC(CCC(NCCOCCOCCNC(OC[C@H]7[C@]8(CCC#CCC[C@]87[H])[H])=O)=O)=O)=O

Molecular Formula

C294H494N52O100

Molecular Weight

6357.36

References & Citations

[1]Toader D, et al. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Mol Cancer Ther. 2023 Sep 5;22 (9) :999-1012.